Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith Trotman

Showing results (51-60 of 148) with videos related to

Pageof 15
Sort By:
Hemasphere|February 27, 2023
Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive After Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 StudyJudith Trotman, Peter Presgrave, Duncan P Carradice, et al.
European Journal of Clinical Pharmacology|October 7, 2022
Challenges associated with test dose pharmacokinetic predictions of high dose melphalan exposure in patients with multiple myelomaChrista Ellen Nath, Andrew Grigg, Sebastian P A Rosser, et al.
Internal Medicine Journal|September 10, 2021
Assessment and management of newly diagnosed classical Hodgkin lymphoma: a consensus practice statement from the Australasian Lymphoma AllianceTara Cochrane, Belinda A Campbell, Shane A Gangatharan, et al.
British Journal of Clinical Pharmacology|February 17, 2016
High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantationChrista E Nath, Judith Trotman, Campbell Tiley, et al.
Blood Advances|April 7, 2022
Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphomaTycel Phillips, Henry Chan, Constantine S Tam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2019
First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up StudyIan W Flinn, Richard van der Jagt, Brad Kahl, et al.
Blood Advances|April 17, 2020
Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYASarah C Rutherford, Michael Herold, Wolfgang Hiddemann, et al.
Internal Medicine Journal|October 19, 2016
Formalising multidisciplinary peer review: developing a haematological malignancy-specific electronic proforma and standard operating procedure to facilitate procedural efficiency and evidence-based clinical practiceJudith Trotman, Jimmy Trinh, Yiu Lam Kwan, et al.
Blood Advances|June 21, 2021
Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphomaConstantine S Tam, Stephen Opat, David Simpson, et al.
Blood Advances|March 22, 2023
Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphomaMaciej Tatarczuch, Mark Waltham, Jake Shortt, et al.
Pageof 15

Showing results (51-60 of 148) with videos related to

Sort By:
Pageof 15
Hemasphere|February 27, 2023
Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive After Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 StudyJudith Trotman, Peter Presgrave, Duncan P Carradice, et al.
European Journal of Clinical Pharmacology|October 7, 2022
Challenges associated with test dose pharmacokinetic predictions of high dose melphalan exposure in patients with multiple myelomaChrista Ellen Nath, Andrew Grigg, Sebastian P A Rosser, et al.
Internal Medicine Journal|September 10, 2021
Assessment and management of newly diagnosed classical Hodgkin lymphoma: a consensus practice statement from the Australasian Lymphoma AllianceTara Cochrane, Belinda A Campbell, Shane A Gangatharan, et al.
British Journal of Clinical Pharmacology|February 17, 2016
High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantationChrista E Nath, Judith Trotman, Campbell Tiley, et al.
Blood Advances|April 7, 2022
Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphomaTycel Phillips, Henry Chan, Constantine S Tam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2019
First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up StudyIan W Flinn, Richard van der Jagt, Brad Kahl, et al.
Blood Advances|April 17, 2020
Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYASarah C Rutherford, Michael Herold, Wolfgang Hiddemann, et al.
Internal Medicine Journal|October 19, 2016
Formalising multidisciplinary peer review: developing a haematological malignancy-specific electronic proforma and standard operating procedure to facilitate procedural efficiency and evidence-based clinical practiceJudith Trotman, Jimmy Trinh, Yiu Lam Kwan, et al.
Blood Advances|June 21, 2021
Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphomaConstantine S Tam, Stephen Opat, David Simpson, et al.
Blood Advances|March 22, 2023
Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphomaMaciej Tatarczuch, Mark Waltham, Jake Shortt, et al.
Pageof 15